Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells

Abstract

Silencing the expression of human papillomavirus (HPV) oncoproteins should have therapeutic benefits for cervical cancer. The authors' objective was to study RNA interference of the HPV 18 E6/E7 bicistronic mRNA with E6 small interfering RNA (siRNA) and E7 siRNA and determine the effect of each siRNA on oncoprotein expression, resultant cell growth, and downstream molecular effects. RNA interference was used to knockdown HPV 18 E6 and E7 oncoproteins on the HPV 18 positive cervical cancer cell lines HeLa and C4I. Western blotting was used to assay for each oncoprotein expression and select downstream molecular targets. Cell cycle analyses, cell viability assays, and colony formation assays were performed to determine the effect of treatment by both HPV 18 E6 siRNA and E7 siRNA. The transfection reagent oligofectamine and Tax siRNA were used as negative controls. Transfection with E6 siRNA caused complete loss of E6 but not E7 oncoprotein. However, E7 siRNA induced complete loss of both E6 and E7 oncoproteins. E6 siRNA mediated the reexpression of p53 protein and a moderate decrease in phosphorylated retinoblastoma protein expression (pRb), resulting in decreased colony formation. Transfection with E7 siRNA mediated a robust increase in p53 expression and complete loss of pRb, resulting in a marked decrease in colony formation compared to the E6 siRNA (P =.001). Flow cytometry revealed significantly increased apoptotic cells with E7 siRNA compared to E6 siRNA and control. RNA interference targeting the E7 portion of the bicistronic HPV 18 mRNA can silence both E6 and E7 oncoproteins and is most effective in cervical cancer growth inhibition.

Keywords

Cervical cancer HPV RNA interference targeted therapy

Get full access to this article

View all access options for this article.

References

Chakrabarti O , Krishna S . Molecular interactions of high risk human papillomaviruses E6 and E7 oncoproteins: implications for tumor progression. J Biosci. 2003;28:337-348.

Pim D , Massimi P , Banks L . Alternatively spliced HPV 18 E6*protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene. 1997;15:257-264.

Zur Hausen H . Papillomaviruses causing cancer: evasion from host cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-698.

Khan MJ , Castle PE , Lorinz AT , et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.

Corden SA , Sant-Cassia LJ , Easton AJ , Morris AG . The integration of HPV-18 DNA in cervical carcinoma. Mol Pathol. 1999;52:275-282.

Thomas M , Pim D , Banks L . The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18:7690-7700.

Bedell MA , Jones KH , Laimens LA . The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3t3 and rat cells. J Virol. 1987;61:3401-3440.

Herber R , Liem A , Pitot H , Lambert PF . Squamous and epithelial hyperplasia in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol. 1996;70:1873-1881.

Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J. 1993;7:872-879.

10.

Alvarez-Salas LM , Cullinan AE , Siwkowski A , Hampel A , Dipaolo JA . Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci U S A. 1998;95:1189-1194.

11.

Choo CK , Ling MT , Suen CKM , Chan KW , Kwong YL . Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol. 2000;78:293-301.

12.

Venturini F , Braspenning J , Homann M , Gismann L , Sczakiel G . Kinetic selection of HPV 16 E6/E7 directed antisense nucleic acids: antiproliferative effect on HPV 16 transformed cells. Nucleic Acids Res. 1999:27:1585-1592.

13.

Scherer LJ , Rossi JJ . Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol. 2003;21:1457-1465.

14.

Sharp P . RNA interference—2001. Genes Dev. 2001;15:485-490.

15.

Elbashir SM , Harborth J , Weber K , Tuschl T . Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002;26:199-213.

16.

Chi J-T , Chang HY , Wang NN , Chang DS , Dunphy N , Brown PO . Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci. 2003;100:6343-6346.

17.

Jiang M , Milner J . Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 2002;21: 6041-6048.

18.

Butz K , Ristriani T , Hengstermann A , Denk C , Scheffner M , Hoppe-Seyler F . siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene. 2003;22:5938-5945.

19.

Hall AHS , Alexander KA . RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol. 2003;77:6066-6069.

20.

Sunaga N , Miyajima K , Suzuki M . Different roles for Caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 2004;64:4277-4285.

21.

Jackson AL , Bartz SR , Schelter J , et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21:635-638.

22.

DeFilippis RA , Goodwin EC , Wu L , DiMaio D . Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence and apoptosis in cervical carcinoma cells. J Virol. 2003;77:1551-1563.

23.

Kastan MB , Onyekwere O , Sidrasky D , Vogelstein B , Craig RW . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.

24.

Jones DL , Munger K . Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol. 1997;71:2905-2912.

25.

Munger K , Basile JR , Duensing S , et al. Biological activities and molecular targets of the human papillomavirus E7 onco-protein. Oncogene. 2001;20:7888-7898.

26.

Bischof O , Nacerddine K , Dejean A . Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol. 2005;25:1013-1024.

27.

Mantovani F , Banks L . The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001;20:7874-7887.